Topics
Glioblastoma | Treatment | Targeted therapy | Ipilimumab
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Ipilimumab
Ipilumab, Nivolumab
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
Ipilumab, Nivolumab, Relatlimab
Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry
KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez
M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U,
Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA,
Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM,
Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H.
Neoadjuvant triplet immune checkpoint
blockade in newly diagnosed glioblastoma.
Nat
Med. 2025 Feb 27. doi:
10.1038/s41591-025-03512-1. PMID:
40016450. Case report. ˍ
Brown NF, McBain C, Brazil L,
Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C,
Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland
P.
Ipilimumab
with temozolomide vs. temozolomide alone after surgery and
chemoradiotherapy in recently diagnosed glioblastoma: a randomized
phase II clinical trial.
Neurooncol
Adv. 2025 May
26;7(1):vdaf032. doi:
10.1093/noajnl/vdaf032. PMID:
40800123. Interventional study. ˍ
ISRCTN.com
ID: ISRCTN84434175.
Ipilimumab; Nivolumab
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD,
Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman
EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl
M, Galbraith K, Dignam JJ, Won M, Mehta MP.
Dual
Immune Check Point Blockade in MGMT-Unmethylated
Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized
Phase II/III Clinical Trial.
J
Clin Oncol. 2025 Aug 8:JCO2500618. doi:
10.1200/JCO-25-00618. PMID:
40779733. Interventional study. ˍ
NRGoncology.org
ID: NRG-BN007.